- Home
- CVM
CVM
Cel-Sci Corporation
as 04-25-2025 4:00pm EST
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | VIENNA |
| Market Cap: | N/A | IPO Year: | 1987 |
| Target Price: | N/A | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.18 - $2.39 | Next Earning Date: | 05-15-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Cel-Sci Corporation News
CVM Breaking Stock News: Dive into CVM Ticker-Specific Updates for Smart Investing
Business Wire
4 days ago
CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
Business Wire
18 days ago
New Study in the Scientific Journal "Cancer Cell" Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses
Business Wire
a month ago
CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients
Business Wire
a month ago
CEL-SCI Announces Closing of $2.5 Million Offering
Business Wire
a month ago
CEL-SCI Announces Pricing of $2.5 Million Offering
Business Wire
a month ago
CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine
Business Wire
a month ago
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression
Business Wire
2 months ago
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
Compare CVM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CVM Cel-Sci Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.